These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 355181)

  • 1. Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.
    Nestoros JN; Lehmann HE; Ban TA
    Int Pharmacopsychiatry; 1978; 13(3):138-50. PubMed ID: 355181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.
    Clark ML; Costiloe JP; Wood F; Paredes A; Fulkerson FG
    Dis Nerv Syst; 1977 Nov; 38(11):943-7. PubMed ID: 913230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of butaclamol in chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    J Clin Pharmacol; 1977; 17(8-9):529-36. PubMed ID: 19510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butaclamol hydrochloride in newly admitted schizophrenics.
    Hollister LE; Davis KL; Berger PA
    Psychopharmacol Commun; 1975; 1(5):493-500. PubMed ID: 778939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
    Imaz F; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.
    Terao T; Oga T; Nozaki S; Ohta A; Ohtsubo Y; Yamamoto S; Zamami M; Okada M
    Acta Psychiatr Scand; 1995 Sep; 92(3):220-4. PubMed ID: 7484202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
    Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of acute clinical response to fluphenazine.
    Levinson DF; Singh H; Simpson GM
    Br J Psychiatry; 1992 Mar; 160():365-71. PubMed ID: 1562863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
    Allan ER; Alpert M; Sison CE; Citrome L; Laury G; Berman I
    J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
    Abuzzahab FS; Zimmerman RL
    J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients.
    Chouinard G; Annable L; Kropsky M
    J Clin Pharmacol; 1978; 18(2-3):148-54. PubMed ID: 24061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholecystokinin appears to have antipsychotic properties.
    Nair NP; Bloom DM; Nestoros JN
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):509-12. PubMed ID: 6891817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of clozapine on symptom clusters in treatment-refractory patients.
    Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC
    J Clin Psychopharmacol; 1997 Feb; 17(1):49-53. PubMed ID: 9004057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
    Lindström LH; Wieselgren IM; Struwe G; Kristjansson E; Akselson S; Arthur H; Andersen T; Lindgren S; Norman O; Naimell L
    Acta Psychiatr Scand Suppl; 1990; 358():130-5. PubMed ID: 1978472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
    Borison RL; Arvanitis LA; Miller BG
    J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics.
    Frangos H; Zissis NP; Leontopoulos I; Diamantas N; Tsitouridis S; Gavriil I; Tsolis K
    Acta Psychiatr Scand; 1978 May; 57(5):436-46. PubMed ID: 354331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
    Keck P; Buffenstein A; Ferguson J; Feighner J; Jaffe W; Harrigan EP; Morrissey MR
    Psychopharmacology (Berl); 1998 Nov; 140(2):173-84. PubMed ID: 9860108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.